Patient Registry Thalidomide Embryopathy

Patient Registry Thalidomide Embryopathy - Registry TE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031883

Enrollment

600

Registered

2023-05-15

Start date

2025-02-04

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q86.80

Interventions

Group 1: People with Thalidomide Embryopathy: The aim of the register is to investigate the effects of congenital malformations against the background of aging using the group of people affected by th

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: People with Thalidomide Embryopathy

Exclusion criteria

Exclusion criteria: People without Thalidomide Embryopathy

Design outcomes

Primary

Measure	Time frame
Setting up a Patient Registry with informations according to ICF-Standard (i)Bodyfunction (ii)Bodystructures (iii)Activities of dayli life and participation (iv)Environmental factors	—

Secondary

Measure	Time frame
Derivation of research hypothesis Derivation of recommendations for provision of medical care and social support	—

Countries

Germany

Contacts

Public ContactRudolf Beyer

Contergansprechstunde, Schön Klinik Hamburg SE & Co KG

rbeyer@schoen-klinik.de+ 49 40 20292363

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026